semaglutide alzheimer trial in early-stage Alzheimer's Disease Novo Nordisk's oral GLP-1 drug

This supports the hypothesis that rapid weight reduction rather than the medication itself is the primary causative factor

The infected mice exhibited a higher increase in interleukin (IL) IL-5, IL-4, and IL-2 than IL-12 and interferon- (IFN-), suggesting an important alteration in cytokine profile from Th1 to Th2 (Figure 2) [38]

It is a science backed approach designed to improve long term quality of life

The most substantial weight loss usually occurs between months 3-6 of treatment

Single-receptor GLP-1 agonists like semaglutide established that pharmacological intervention could produce meaningful, sustained weight loss

Semaglutide operates by mimicking the hormone GLP-1, influencing brain areas that regulate appetite